G. Mike Makrigiorgos
YOU?
Author Swipe
View article: The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer
The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer Open
Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking estrogen (ER), progesterone (PR), and human epidermal growth factor receptor (HER‐2) expression. It disproportionately affects women of African desc…
View article: Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma Open
Despite responses of chimeric antigen receptor (CAR)-T cells in patients with relapsed/refractory large B-cell lymphoma (LBCL), over half of patients eventually relapse. Methods to detect early disease persistence are needed to identify pa…
View article: 404P MRD analysis following curative intent treatment in patients with locally advanced esophageal cancer utilizing MAESTRO, an ultrasensitive ctDNA assay
404P MRD analysis following curative intent treatment in patients with locally advanced esophageal cancer utilizing MAESTRO, an ultrasensitive ctDNA assay Open
View article: Genome-wide extraction of differentially methylated DNA regions using adapter-anchored proximity primers
Genome-wide extraction of differentially methylated DNA regions using adapter-anchored proximity primers Open
The epigenetic deregulation of CpG islands (CGIs) plays a crucial role in cancer initiation and progression. CGIs comprise 1-2% of the human genome and are rich in differentially methylated regions (DMRs) that can serve as cancer biomarker…
View article: Methyl-CODEC enables simultaneous methylation and duplex sequencing
Methyl-CODEC enables simultaneous methylation and duplex sequencing Open
DNA mutations and methylation often contribute to disease development in a synergistic manner. While duplex sequencing is the most accurate method for detecting DNA mutations, it typically lacks the ability to simultaneously assess methyla…
View article: Aerosol Delivery of Hesperetin-Loaded Nanoparticles and Immunotherapy Increases Survival in a Murine Lung Cancer Model
Aerosol Delivery of Hesperetin-Loaded Nanoparticles and Immunotherapy Increases Survival in a Murine Lung Cancer Model Open
Flavonoids, like Hesperetin, have been shown to be an ACE2 receptor agonists with antioxidant and pro-apoptotic activity and can induce apoptosis in cancer cells. ACE2 receptors are abundant in lung cancer cells. Here, we explored the appl…
View article: Immediate postoperative minimal residual disease detection with MAESTRO predicts recurrence and survival in head and neck cancer patients treated with surgery
Immediate postoperative minimal residual disease detection with MAESTRO predicts recurrence and survival in head and neck cancer patients treated with surgery Open
Purpose While circulating tumor DNA (ctDNA) is a promising biomarker for minimal residual disease (MRD) detection in head and neck squamous cell carcinoma (HNSCC), more sensitive assays are needed for accurate MRD detection at clinically-r…
View article: Methyl-CODEC enables simultaneous methylation and duplex sequencing
Methyl-CODEC enables simultaneous methylation and duplex sequencing Open
DNA mutations and methylation often contribute to disease development in a synergistic manner. While duplex sequencing is the most accurate method for detecting DNA mutations, it typically lacks the ability to simultaneously assess methyla…
View article: Early Measurable Residual Disease Detection after CAR-T is Associated with Poor Outcome Large B-cell Lymphoma Patients
Early Measurable Residual Disease Detection after CAR-T is Associated with Poor Outcome Large B-cell Lymphoma Patients Open
Despite responses of chimeric antigen receptor (CAR)-T cells in relapsed/refractory (R/R) large B cell lymphoma (LBCL) patients, over half of patients eventually relapse. Methods to detect early disease persistence are needed to identify p…
View article: Aerosol delivery of immunotherapy and Hesperetin-loaded nanoparticles increases survival in a murine lung cancer model
Aerosol delivery of immunotherapy and Hesperetin-loaded nanoparticles increases survival in a murine lung cancer model Open
Purpose Studies have shown that flavonoids like Hesperetin, an ACE2 receptor agonist with antioxidant and pro-apoptotic activity, can induce apoptosis in cancer cells. ACE2 receptors are abundant in lung cancer cells. Here, we explored the…
View article: Pyrimidine-Dependent UV-Mediated Cross-Linking Magnifies Minor Genetic or Epigenetic Changes in Clinical Samples
Pyrimidine-Dependent UV-Mediated Cross-Linking Magnifies Minor Genetic or Epigenetic Changes in Clinical Samples Open
Background Detection of minor DNA allele alterations is becoming increasingly important for early detection and monitoring of cancer. We describe a new method that uses ultraviolet light to eliminate wild-type DNA alleles and enables impro…
View article: MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies
MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies Open
Background Tracing patient-specific tumor mutations in cell-free DNA (cfDNA) for minimal residual disease (MRD) detection is promising but challenging. Assaying more mutations and cfDNA stands to improve MRD detection but requires highly a…
View article: Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 Open
View article: Single duplex DNA sequencing with CODEC detects mutations with high sensitivity
Single duplex DNA sequencing with CODEC detects mutations with high sensitivity Open
Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (‘single duplexes’) to disce…
View article: Supplementary Figures S1 and S2 from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation
Supplementary Figures S1 and S2 from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation Open
Figure S1. Drug dose-dependent enhancement of γ-H2AX and Rad51 expression using NanoOlaparib; Figure S2. Representative confocal microscopy images of Rad51 and Polθ immunostaining 30 minutes following irradiation.
View article: Data from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation
Data from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation Open
The use of PARP inhibitors in combination with radiotherapy is a promising strategy to locally enhance DNA damage in tumors. Here we show that radiation-resistant cells and tumors derived from a Pten/Trp53-deficient mouse model of a…
View article: Data from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation
Data from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation Open
The use of PARP inhibitors in combination with radiotherapy is a promising strategy to locally enhance DNA damage in tumors. Here we show that radiation-resistant cells and tumors derived from a Pten/Trp53-deficient mouse model of a…
View article: Supplementary Figures S1 and S2 from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation
Supplementary Figures S1 and S2 from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation Open
Figure S1. Drug dose-dependent enhancement of γ-H2AX and Rad51 expression using NanoOlaparib; Figure S2. Representative confocal microscopy images of Rad51 and Polθ immunostaining 30 minutes following irradiation.
View article: Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Supplementary Methods
View article: Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
MRD testing results in early stage breast cancer cohort. (A) Detection limits versus the number of SNVs tracked for each cfDNA sample. (B) Comparison of fingerprint size distributions between patients that were MRD+ at any time point and t…
View article: Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Supplementary Tables
View article: Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who experienced local recurrence only after treatment for early stage breast cancer. cfDNA time points for all patients who experienced local recurrence only. End points represent time of last follow up or death.
View article: Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who were recurrence free after treatment for early stage breast cancer. cfDNA time points for all patients who did not experienced recurrence. Those marked with poor detection limits had an estimated detection limit worse than 1/1…
View article: Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Overview schematic of MRD assay. MRD assay workflow from characterizing a primary tumor to determining if a blood draw contains evidence of residual disease.
View article: Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Technical performance of the MRD Assay. All samples from early stage breast cancer cohort. Includes plasma cfDNA and buffy coat gDNA samples. Samples from the same patient and probed with the same panel are represented independently. (A) O…
View article: Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
MRD testing results in early stage breast cancer cohort. (A) Detection limits versus the number of SNVs tracked for each cfDNA sample. (B) Comparison of fingerprint size distributions between patients that were MRD+ at any time point and t…
View article: Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who experienced distant recurrence after treatment for early stage breast cancer. cfDNA time points for patients who ultimately experienced distant recurrence. Those marked with poor detection limits had an estimated detection lim…
View article: Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Early stage breast cancer cohort. (A) Overview of subtype distribution of cohort as well as the timing of blood draws relative to surgery and treatment. (B) REMARK diagram of the early stage breast cancer cohort. (C) Distribution of the nu…
View article: Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who experienced distant recurrence after treatment for early stage breast cancer. cfDNA time points for patients who ultimately experienced distant recurrence. Those marked with poor detection limits had an estimated detection lim…
View article: Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Early stage breast cancer cohort. (A) Overview of subtype distribution of cohort as well as the timing of blood draws relative to surgery and treatment. (B) REMARK diagram of the early stage breast cancer cohort. (C) Distribution of the nu…